Duarte, Calif.-based City of Hope researchers have developed a way to modify CAR T cells after infusion, an approach designed to help the therapy adapt as tumors change.
The preclinical study on the technology was published Sept. 7 in Cancer Immunology Research.
The new platform relies on a molecular “docking system” that lets researchers attach add-on molecules to the cells, according to a Sept. 22 news release.
Those add-ons made the cells easier to monitor, supported their growth and broadened the types of cancer cells they could target. Existing CAR T therapies are fixed once they reach the bloodstream. When tumors evolve to avoid detection, the therapy can stop working.
“The power of this platform is its flexibility,” co-senior author Christine Brown, PhD, deputy director of T Cell Therapeutics Research Laboratories at City of Hope, said in the news release.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
